OpenAI in Talks with FDA to Accelerate Drug Approvals Using AI
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.